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A Novel Fluorescence Method
for the Rapid Detection of Functional
1-Adrenergic Receptor Autoantibodies in Heart Failure
Viacheslav O. Nikolaev, PHD,* Valérie Boivin, PHD,* Stefan Störk, MD, PHD,†
Christiane E. Angermann, MD,* Georg Ertl, MD,† Martin J. Lohse, MD,* Roland Jahns, MD*†
Würzburg, Germany
Objectives This study sought to develop a rapid method for the detection of activating autoantibodies directed against the
1-adrenoceptor (anti-1-Abs) in patients with heart failure.
Background The anti-1-Abs are supposed to play a pathophysiological role in heart failure. However, there is no reliable
method for their detection. With a complex screening strategy (enzyme-linked immunosorbent assay, immuno-
fluorescence, cyclic adenosine monophosphate [cAMP]–radioimmunoassay) we have previously identified anti-
bodies targeting the second extracellular 1-receptor loop (anti-1-ECII) in 13% of patients with ischemic cardio-
myopathy (ICM) and in 26% with dilated cardiomyopathy (DCM).
Methods To detect anti-1-Abs, we measured 1-receptor–mediated increases in intracellular cAMP by fluorescence reso-
nance energy transfer using a highly sensitive cAMP sensor (Epac1-based fluorescent cAMP sensor).
Results The immunoglobulin G (IgG) prepared from 77 previously antibody-typed patients (22 ICM/55 DCM) and 50 matched
control patients was analyzed. The IgG from all 22 previously anti-1-ECII–positive patients (5 ICM/17 DCM) induced a
marked cAMP increase, indicating receptor activation (49.8 4.2% of maximal isoproterenol-induced signal). The IgG
from control patients and 32 previously anti-1-ECII–negative patients (17 ICM/15 DCM) did not significantly affect
cAMP. Surprisingly, our technology detected anti-1-Abs in 23 DCM patients formerly judged antibody-negative, but
their cAMP signals were generally lower (31.3 6.8%) than in the previous group. “Low”-activator anti-1-Abs were
blocked preferentially by peptides corresponding to the first, and “high”-activator anti-1-Abs by peptides correspond-
ing to the second 1-extracellular loop. Beta-blockers alone failed to fully prevent anti-1-ECII–induced receptor activa-
tion, which could be achieved, however, by the addition of 1-ECII peptides.
Conclusions Our novel method of detecting anti-1-Abs proved to be fast and highly sensitive. It also revealed an insuffi-
cient ability of beta-blockers to prevent anti-1-ECII–induced receptor activation, which opens new venues
for the research on anti-1-Abs and eventual treatment options in heart failure. (J Am Coll Cardiol 2007;
50:423–31) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.051p
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dver the past 2 decades, evidence has accumulated from both
nimal-based and patient-based studies that functionally active
utoantibodies targeting the human 1-adrenergic receptor
anti-1-Abs) may play an important role in the development
nd clinical course of progressive cardiac dilatation and failure
1,2). The anti-1-Abs were initially described in up to 50% of
rom the *Institut für Pharmakologie und Toxikologie, and the †Medizinische Klinik
nd Poliklinik I, Herz- und Kreislaufzentrum, University of Würzburg, Würzburg,
ermany. Drs. Nikolaev and Boivin contributed equally to this work. Supported by
he Deutsche Forschungsgemeinschaft, Bonn, Germany (SFB487, Grant Ja 706/2-4,
nd Leibniz award to Dr. Lohse), and the Fonds der Chemischen Industrie, Frankfurt
m Main, Germany. The University of Würzburg has filed for patent protection of
he diagnostic method described in this article.n
Manuscript received July 21, 2006; revised manuscript received February 1, 2007,
ccepted March 20, 2007.atients with Chagas’ cardiomyopathy (3,4). Later, they also
ere detected in patients with myocarditis (5), and in patients
ith chronic heart failure caused by ischemic cardiomyopathy
ICM) or dilated cardiomyopathy (DCM) (5–7). In DCM
atients, anti-1-Abs positivity has been linked to a more
epressed left ventricular function (6), a higher prevalence of
erious ventricular arrhythmias (8,9), and a higher incidence of
udden cardiac death (9). The definition of antibody positivity,
owever, depended on highly divergent screening methods
sed in these studies (i.e., enzyme-linked immunosorbent assay
ELISA] with receptor peptides, Western blotting of heart
issues, functional assays with neonatal rat cardiomyocytes, or
etection by surface plasmon resonance [6,7,9–13]). Until
ow, this issue has not been solved satisfactorily.
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screening procedure composed of
an ELISA with synthetic recep-
tor peptides as well as immuno-
fluorescence and cyclic adenosine
monophosphate (cAMP) re-
sponses in cells expressing native
human -adrenergic receptors
(-ARs), have screened 104
heart failure patients and 108
matched healthy control patients
for functionally active anti-1-
Abs. According to this screening
procedure, the prevalence of
stimulating anti-1-Abs was
1% in healthy patients, about
10% in ICM patients, and 26%
in DCM patients (6). Interest-
ingly, the prospective follow-up
of these patients over more than
10 years showed an almost 3-fold
increased cardiovascular and all-
cause mortality risk in anti-1-
Abs–positive compared with an-
tibody–negative DCM patients
(14). By contrast, no stimulating
anti-1-Abs were detected in pa-
tients with hypertensive or valvu-
lar heart disease (15).
In our studies, the definition
of functionally active anti-1-
Abs was based mainly on their
effects on receptor-mediated sig-
aling (i.e., their effects on cellular cAMP levels and on the
ctivity of the cAMP-dependent protein kinase [PKA]).
yclic AMP is a universal second messenger of many G
rotein-coupled receptors, including the -adrenergic re-
eptor family. It exerts its effects via PKA, cAMP-gated ion
hannels, phosphodiesterases, and exchange proteins di-
ectly activated by cAMP (Epac1 and 2) (16). In recent
ears, several fluorescence methods have been developed to
easure cAMP in intact cells. Fluorescence resonance
nergy transfer (FRET) between green fluorescent protein
ariants fused to the regulatory and catalytic subunits of
KA has been described to study the spatio-temporal
ynamics of cAMP in neurons (17) or cardiac myocytes
18). More recently, we have reported the development of
ovel single-chain fluorescence indicators by fusing en-
anced cyan fluorescent protein (CFP) or yellow fluorescent
rotein (YFP) directly to the cAMP binding domain of
pac proteins, which allowed achievement of a higher
ensitivity and better temporal resolution of the cAMP
easurements (19,20). Here, we decided to take advantage
f this novel tool to analyze the prevalence of functionally
ctive anti-1-Abs in a cohort of previously antibody-typed
Abbreviations
and Acronyms
anti-1-Abs  activating
autoantibodies against the
1-adrenergic receptor
1-AR  1-adrenergic
receptor/1-adrenoceptor
1-ECI  the first
extracellular loop of the
1-adrenergic receptor
1-ECII  the second
extracellular loop of the
1-adrenergic receptor
cAMP  cyclic adenosine
monophosphate
CFP  cyan fluorescent
protein
DCM  dilated
cardiomyopathy
Epac1-camps  Epac1-
based fluorescent cAMP
sensor
FRET  fluorescence
resonance energy transfer
GST  glutathione-S-
transferase
ICM  ischemic
cardiomyopathy
isomax  maximal signal
induced by isoproterenol
PKA  protein kinase A
YFP  yellow fluorescent
proteinatients with heart failure caused by DCM or ICM, and to itudy the ability of -blockers to inhibit anti-1-Abs–
nduced receptor activation.
ethods
AMP measurements by Epac-FRET. To establish a
ovel cell-based method for the detection of functional
nti-1-Abs, human embryonic kidney HEK293 cells stably
xpressing human 1-AR (0.4 pmol/mg membrane protein)
ere transiently transfected with Epac1-based fluorescent
AMP sensor (Epac1-camps) using calcium phosphate
recipitation. Twenty-four to 48 h after transfection, cAMP
easurements were performed microscopically as described
19). The cells were maintained in buffer A (144 mmol/l
aCl, 5 mmol/l KCl, 2 mmol/l CaCl2, 1 mmol/l MgCl2, 20
mol/l HEPES, pH  7.3), supplemented with 50 nmol/l
CI 118551 (Sigma, Deisenhofen, Germany) to avoid
ross-reactivity with the endogenous 2-AR (approximately
.1 pmol/mg according to binding assays, data not shown).
he immunoglobulin G (IgG) preparations were diluted in
he same buffer and added to the cells at 0.13 g/l protein
oncentration. (-)Isoproterenol (Sigma) was used to deter-
ine the maximal cAMP response.
locking experiments. To determine relevant epitopes for
he anti-1-Abs, we incubated them with peptides (0.5
g/l) derived from the human 1-ECI (AGRWEYGS-
FCELQ) and 1-ECII sequences (ARAESDEAR-
CYNDPKCCDFVTNRE) (21) for 6 h at 4° C. A peptide
orresponding to the 2-ECII sequence (ATHQEAIN-
YANETCCDFFTNRE) (22) served to control for spec-
ficity. Cyclic AMP signals were then measured by Epac-
RET and compared with those of unblocked IgG
reparations. To inhibit receptor signaling by functional
nti-1-Abs, we used the clinically relevant -AR antago-
ists alprenolol, metoprolol (Sigma), bisoprolol (Merck,
armstadt, Germany), and carvedilol (provided by Dr. S.
ngelhardt).
atients and samples. The IgG preparations available
rom 77 previously analyzed patients with heart failure
aused by DCM (n  55) or ICM (n  22) (6,15) were
ncluded in the present study. Diagnosis of DCM had been
ased on a left ventricular end-diastolic volume 110
l/m2 and an ejection fraction 55% (determined by
entriculography) together with an exclusion of coronary
eart disease (by angiography) (6). No exposure to cardio-
oxic substances, myocarditis, or other systemic heart disease
as evident from medical history in these patients. At the
ime of sample acquisition, all patients had been in stable
emodynamic condition and none of them had received
-blocking agents or sympathomimetic substances. Table 1
ummarizes the clinical and hemodynamic data of the
atients (DCM, n  55; ICM, n  22) whose IgG
reparations were analyzed. Control subjects (n  50) were
elected from healthy blood donors, and matched for gender
nd age. All assays were carried out with IgG fractions
solated by caprylic acid precipitation and normalized to
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July 31, 2007:423–31 Detection of 1-Receptor Antibodiesotal IgG concentration (800 g/ml), as described previ-
usly (6,15,23). For the assays, IgG prepared from anti-1-
CII–positive Lewis/CrlBR rats with dilated immune-
ardiomyopathy (generated by immunization against a
1-ECII/glutathione-S-transferase [GST] fusion protein),
nti-1-ECI antibodies prepared from Lewis rats immu-
ized with a 1-ECI/GST fusion protein, and IgG from
orresponding isogenic anti-1-Abs–negative rats served as
ositive or negative controls, respectively (24). The study
as approved by the Medical Ethics Committee of the
niversity of Würzburg.
tatistics. Data are presented as median (interquartile
ange) or absolute numbers (percent), as appropriate. In
gures, data are shown as mean (SEM). Continuous data
ere analyzed by 1-way analysis of variance (blocking exper-
ments) and the Student t test. Statistical analysis was per-
ormed using SPSS 13.0.1 (SPSS Inc., Chicago, Illinois). After
onfirming normal distribution of the measured FRET signals
by applying the Kolmogorov-Smirnov test), Gaussian distri-
ution curves per subgroup were generated using Origin 6.1
OriginLab Corp., Northampton, Massachusetts). All p values
re reported 2-sided. A p value 0.05 was considered statis-
ically significant.
esults
etection of functionally active anti-1-Abs with a
uorescent Epac-sensor. To determine the anti-1-Abs
ia receptor-induced cAMP accumulation in 1-AR ex-
ressing HEK293 cells, we used a recently developed
uorescent cAMP sensor (Epac1-camps). The sensor de-
ects intracellular cAMP with high spatial and temporal
esolution by changes in FRET between CFP and YFP
used to the cAMP binding site of Epac1 (Fig. 1A).
ompared with conventional radioimmunoassay (RIA)
AMP detection systems, the new FRET assay has an about
0-fold higher sensitivity, rendering this method suitable
or the detection of small changes in intracellular cAMP
linical and Hemodynamicata of Patients With DCM and ICM
Table 1 Clinical and HemodynamicData of Patients With DCM and ICM
Parameter DCM (n  55) ICM (n  22)
Age, yrs 56 (51–65) 58 (54–65)
Female 8 (14.5) 3 (13.6)
New York Heart
Association functional
class, II/III/IV
14 (25)/23 (42)/18 (33) 8 (36)/10 (46)/4 (18)
Heart rate, beats/min 79 (71–92) 87 (78–95)
PVR, dyne  s/cm5 151 (105–179) 140 (99–168)
SVR, dyne  s/cm5 1,425 (1,185–1,726) 1,460 (1,224–1,628)
Ejection fraction, % 36 (28–44) 36 (23–49)
Cardiac index, l/min  m2 2.61 (2.11–3.10) 2.55 (2.10–3.18)
Contractility, mm Hg/s 1,180 (980–1,420) 1,487 (1,110–1,837)
Relaxation, mm Hg/s 1,040 (880–1,240) 1,064 (902–1,328)
ata are median (interquartile range) or n (%).
DCM  dilated cardiomyopathy; ICM  ischemic cardiomyopathy; PVR  peripheral vascular
esistance; SVR  systemic vascular resistance.evels (Fig. 1B). To test whether this technology can be usedo detect antibodies activating the 1-AR, we used IgG
ractions from anti-1-ECII–positive Lewis/CrlBR rats
ith dilated immune cardiomyopathy and isogenic control
Figure 1 Detection of Functional Rat
Anti-1-Abs by a Novel FRET-Based Assay
Cell-based approach for the detection of functional activating autoantibodies
against the 1-adrenergic receptor (anti-1-Abs). (A) Receptor activation
induced by binding of antibodies to its accessible extracellular loops leads to
an increase in cyclic adenosine monophosphate (cAMP) through sequential
activation of Gs proteins and adenylyl cyclase (AC). The cAMP is detected by
fluorescence resonance energy transfer (FRET) (grey arrow) between cyan fluo-
rescent proteins (CFP) and yellow fluorescent proteins (YFP) fused to the cAMP-
binding domain of Epac1. The sensor (Epac1-based fluorescent cAMP sensor
[Epac1-camps]) changes its conformation upon cAMP binding (black arrow),
resulting in a decrease in FRET. (B) Measuring cAMP levels in isoproterenol
(Iso)-stimulated human embryonic kidney HEK293 cells stably expressing
human 1-AR by conventional radioimmunoassay (RIA) (Amersham, Freiburg,
Germany) or Epac-FRET. One of 3 independent RIA concentration-response
curves (EC50  0.53  0.19 nmol/l) is shown. The cAMP range that can be
monitored by Epac-FRET until it gets saturated is presented by 2 horizontal
dotted lines. At 0.05 nmol/l isoproterenol, Epac1-camps becomes satu-
rated, indicating an intracellular cAMP concentration of approximately 20
mol/l (according to in vitro measurements in cell lysates with pure cAMP
[19]). This extremely sensitive sensor is characterized by a high dynamic
range at physiologically relevant cAMP concentrations 0.1 to 20 mol/l
(which are covered by only 15% of the maximal cAMP-RIA signal), making
minor cAMP changes previously undetected by conventional assays well detect-
able by Epac-FRET. (C) The immunoglobulin (Ig)G prepared from rats immunized
with glutathione-S-transferase (GST) fusion proteins containing the first (ECI-immu-
nized, center) or second extracellular loop of the human 1-AR (ECII-immunized,
right) were assayed for activity using human embryonic kidney HEK293 cells
stably expressing human 1-AR transfected with Epac1-camps, and compared
with nonimmunized animals (control animals, left) to assess the reliability of
the method. Representative FRET ratio traces of 1 of 6 independent experi-
ments are presented (% corresponds to the relative change in YFP/CFP inten-
sity ratio). The decrease in FRET reflects an increase in intracellular cAMP.
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Detection of 1-Receptor Antibodies July 31, 2007:423–31ats (24). None of the IgG preparations from the control
ats significantly affected cAMP levels in 1-AR expressing
EK293 cells, whereas the IgG preparations from immu-
ized rats containing functionally active anti-1-ECII anti-
odies produced clear-cut signals and induced a rapid and
ronounced loss in Epac-FRET (Fig. 1C, right). The
RET signal produced by these antibodies corresponded to
bout 75% of the maximal signal induced by isoproterenol
isomax). Next, we tested the functional effects of rat anti-
odies generated by active immunization against the first
1-EC loop (human) fused to bacterial GST. Interestingly,
hese rat anti-1-ECI antibodies also stimulated cAMP
roduction, but the FRET signals induced were signifi-
antly lower than those induced by rat anti-1-ECII, yield-
ng only approximately 40% of isomax (Fig. 1C, center). The
nset of both the anti-1-ECII–provoked and the anti-1-
CI–provoked responses occurred with an initial delay of
00 to 150 s compatible with slow binding kinetics of the
ntibodies and the resultant conformational rearrangement
f the receptor molecule. These experiments with anti-1-
bs generated in rats suggested that our novel method also
ight be suitable for the detection of anti-1-Abs in
atients.
igh prevalence of anti-1-Abs in DCM patients. We
hen analyzed IgG preparations that were available from
reviously antibody-typed DCM patients (n  55) (6) and
ealthy control patients (n  50) matched for gender and
ge. None of the IgG preparations from healthy control
atients significantly altered Epac-FRET signals (Fig. 2A,
eft). In contrast, IgG preparations from all 17 DCM
atients previously judged anti-1-Abs–positive induced a
arked and rapid loss of FRET signals, indicating an
ncrease in intracellular cAMP caused by 1-AR activation
49.5  3.9% of isomax; Abs) (Fig. 2A, right), similar to
he responses obtained with activating rat anti-ECII-Abs.
urprisingly, we detected anti-1-Abs also in 23 of 38
60%) DCM patients formerly judged antibody-negative
Abs–) (Fig. 2A, center), but the cAMP signals induced by
hese antibodies were significantly lower than in the
revious group (31.3  6.8%, p  0.001 [Student t test])
Fig. 2A, center). At first sight, their effects on cAMP
roduction seemed to be comparable with those of low-
ctivating rat anti-1-Abs, generated against the human
1-ECI loop.
To perform a systematic analysis of the different (human)
nti-1-Abs–induced cAMP responses, we plotted distri-
ution histograms of the amplitude of the FRET signals for
CM patients and for healthy control patients, respectively.
n the latter, we observed a single peak Gaussian distribu-
ion of the FRET signals ranging from 13.0% to 18.6%
f isomax, with a mean value of 5.0  6.2%. Positivity was
hus defined as a FRET signal above 2 SD of the mean
alue of healthy control patients (i.e., 17.4% [5.0%  2 
.2%]). In contrast to the single peak Gaussian distribution
f the healthy control patients, the histogram for DCM
atients showed a multiple peak distribution pattern. Sub- pequent iteration of the respective FRET values assuming a
ultipeak Gaussian model produced the best fit for a
-peak Gaussian distribution, yielding a R2  0.98 (R2 
.47 or 0.77 for the 1- or 2-peak Gaussian distribution,
espectively). The 55 DCM patients tested were then
rouped at the respective intersection points of the 3
alculated Gaussian curves (Fig. 2B). Fifteen of 55 (28%)
Figure 2 FRET Detection of
Functional Anti-1-Abs in Patients
Measuring cAMP by Epac-FRET detects functional anti-1-Abs in dilated cardio-
myopathy (DCM) patients. (A) None of the IgG prepared from healthy control
patients (n  50) induced a significant cAMP response in living cells (left). The
IgG from DCM patients previously judged anti-1-Abs-positive (15) (Abs) elic-
ited marked cAMP responses (49.5  3.8% of maximal Iso signal, right).
The IgG from 23 of 38 (60%) previously anti-1-Abs-negative judged patients (6)
(Abs) showed a robust but significantly smaller increase in cAMP (31.3 
6.8%, p  0.01 according to the Student t test, center). Representative experi-
ments of at least 3 different cells for each IgG preparation are shown. (B)
Histogram with Gaussian distribution curves based on the strength of the FRET
signal in healthy control patients versus DCM patients (R2  0.98 for a 3-peak
Gaussian distribution). The antibody induced FRET signals allow discrimination
of 3 groups of activity: no activity (n  15), low activity (n  22), high activity
(n  18); grouping was performed as described in the text. (C) Frequency and
distribution of FRET signals obtained with IgG preparations from n  22
previously antibody-typed ischemic cardiomyopathy (ICM) patients. Five of
them showed high FRET activity, and the remainder was classified antibody-
negative. (D) Concentration-response relationship between high-activator
and low-activator IgG showing significantly different activation capacities
over a wide range of antibody concentrations (p  0.05; Student t test).
The percent  SEM of maximal Iso-induced cAMP responses is presented
(normalized to maximal changes in FRET induced by high-activator anti-1-
Abs; representative experiments, n  4). Abbreviations as in Figure 1.atients showed FRET signals below the lower intersection
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July 31, 2007:423–31 Detection of 1-Receptor Antibodiescutoff) point of 18.2% FRET response and were thus
rouped negative (Abs–); all those patients also had been
orrectly grouped Abs– using the former screening algo-
ithm. The remaining n  40 of 55 (72%) patients were
rouped at the upper intersection (cutoff) point of 41.9%
RET response as low (n  22 of 55, 40%) or high
ctivators (n  18 of 55, 33%), respectively (Fig. 2B). All
n  17) previously identified anti-1-Abs–positive DCM
atients and 1 patient unidentified with the former meth-
dology were classified high activators, whereas all (n  22)
ow activators (18.2%  FRET signal 41.9%) had been
udged Abs– with the former screening algorithm.
In summary, the analysis of Epac-FRET signals from the
rst patient collective analyzed showed an anti-1-Abs
revalence of more than 70% (n  40 of 55) in DCM,
hich is higher than obtained by the ELISA/
mmunofluorescence/cAMP-RIA screening procedure (6).
t seems that the Abs group can be separated into 2
ubgroups on the basis of the FRET data, which were
lassified as low activators (FRET amplitude 18.2% to
1.9% of isomax) and high activators (FRET amplitude
42% of isomax).
Next, we analyzed n  22 still available IgG preparations
rom a previously antibody-typed ICM collective (6,15).
ive previously antibody-positive judged patients had anti-
1-Abs producing strong FRET signals in a range of those
lassified high activators (Fig. 2C). In contrast, IgG prep-
rations from the other 17 ICM patients (previously judged
ntibody-negative) did not produce any significant FRET
ignals, indicating that low-activator anti-1-Abs probably
re not a typical feature of ICM.
As a consequence, the 2 newly identified FRET-positive
CM populations were studied in more detail. Analyzing
he concentration response relationship, we found that
ow-activator IgG, even at higher concentrations, did not
nduce cAMP levels of a similar order of magnitude as
igh-activator IgG (Fig. 2D). This finding renders lower
iters of anti-1-Abs in sera of low activators an unlikely
xplanation for the lower cAMP response, but rather
uggests a different mechanism of action of this type of
nti-1-Abs at the receptor level.
igh or low activating capacity defines anti-1-Abs
gainst different epitopes. As suggested by the data ob-
ained with our rat anti-1-Abs, one reason for qualitative
ifferences between antibodies in terms of FRET activity
ight be differences in the receptor epitopes targeted by
ifferent anti-1-Abs. Previously, the occurrence of func-
ional anti-1-Abs against 1-ECII and 1-ECI, but not
1-ECIII, has been reported in DCM patients (11). In
ddition, functional anti-1-Abs against the 1-ECII and
1-ECI epitopes have also been generated successfully in
nimals by immunization, suggesting a certain antigenicity
f these 2 epitopes (25). To analyze whether different
argeted epitopes might account for high or low FRET
ctivating capacities of the anti-1-Abs detected in our
CM patients, we incubated them with synthetic peptidesorresponding to 1-ECII or to 1-ECI and analyzed the
locking effect of each of these peptides. These experiments
howed that FRET signals of high-activator IgG could be
locked specifically by peptides corresponding to 1-ECII,
Figure 3 Functional Anti-1-Abs
Target Distinct Receptor Epitopes
Blocking experiments for different classes of functional anti-1-Abs. (A) The
cAMP generation induced by high-activator IgG is attenuated only by specific
peptides derived from the second extracellular 1-AR loop (1-ECII). (B) Low-
activator signals could be blocked in all instances by peptides corresponding
to the first extracellular 1-AR loop (1-ECI) but not by 1-ECII peptides (repre-
sentative experiments from at least 3 cells per condition are shown). Analysis
of the kinetics of the different FRET responses is presented in the lower pan-
els of (A) and (B). Ratio traces were fitted with a mono-exponential function,
and the time constant of the decay of the respective FRET signals was deter-
mined. In both cases, the effects of ECI and ECII peptides differ significantly
(*p  0.05, **p  0.01; one-way analysis of variance [ANOVA]). (C) Columns
represent mean  SEM (error bars) of cAMP responses induced by (n  7)
representative high-activator IgG, or (D) (n  10) representative low-activator
IgG prepared from DCM patients in the absence (n.b.  not blocked) or pres-
ence of peptides corresponding to the first (ECI) and/or second extracellular
1-AR loop (ECII), or to ECII of the 2-AR. Statistical significance was tested
by one-way ANOVA (**p  0.01 compared with the n.b. group). (E) Dose-
response curve showing the effect of increasing concentrations of the 1-ECII
peptide on the inhibition of high-activator-induced cAMP responses (representa-
tive experiments, n  5). The curve was fitted to the data using Origin 6.1
(OriginLab Corp., Northampton, Massachusetts) assuming a single binding site.
Abbreviations as in Figures 1 and 2.
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Detection of 1-Receptor Antibodies July 31, 2007:423–31ut not by peptides corresponding to 1-ECI or by a control
eptide derived from ECII of the 2-AR (7 patients tested)
Figs. 3A and 3C). Concentration-response analysis of the
1-ECII peptide showed that the peptide concentrations
sed in our experiments (0.5 g/l) were able to produce a
aximal inhibitory effect (Fig. 3E). Although we could
chieve a partial, about 50%, inhibition of high-activator
gG by 1-ECII peptides alone, simultaneous blocking with
CI and ECII peptides did not achieve a further decrease in
AMP signals (Figs. 3C and 3D). In contrast, low-activator
gG was inhibited only by 1-ECI peptides (10 patients
ested) (Figs. 3B and 3D) and again, a combination of ECI
nd ECII peptides did not enhance inhibition (Figs. 3C and
D). All sera from DCM patients with functional anti-1-
bs yielding cAMP signals near the cut-off value between
o and low as well as low and high activators were studied
n detail by such blocking experiments to ascertain the
ccuracy of our classification. The only patient previously
udged Abs with IgG eliciting strong Epac-FRET signals
45.4% FRET signal) was confirmed as having high-
ctivator IgG autoantibodies blockable by 1-ECII peptides.
n addition, 2 patients with IgG yielding about 40% FRET
esponse (39.9% and 40.1%, respectively; classified low
ctivators according to the upper intersection point of
1.9%) were equally inhibited by the 1-ECII peptide,
hereas all the other low-activator IgG tested (n  20 of
5, Epac-FRET responses between 20% to 39%) were
nhibited only by the 1-ECI peptide. These data are
onsistent with the hypothesis that the differences in cAMP
roduction of high and low activators most likely reflect the
ifferent epitopes targeted and different active receptor
onformations induced. However, to address the question of
hether the differences in type, target domain, and activat-
ng capacity of anti-1-Abs might be prognostically (and
hus clinically) relevant in the course of heart failure, a
ystematic screening of larger patient populations with the
ovel FRET method is needed.
-blockers do not fully abolish high-activator-induced
AMP signals. Blockade of sympathetic hormone recep-
ors by -receptor antagonists has proven beneficial in heart
ailure (26). Thus, one possible strategy to combat func-
ional anti-1-Abs in antibody-positive patients might be
he pharmacological neutralization of autoantibody-
ediated stimulatory effects (2). Therefore, we analyzed the
ffects of a panel of clinically relevant -receptor antagonists
n anti-1-Abs–mediated cAMP increases (i.e., antibody-
nduced Epac-FRET signals) in our transfected cell system.
oth 1-selective (bisoprolol, metoprolol) and nonselective
alprenolol, carvedilol) beta-blockers largely diminished the
nti-1-ECII–induced cAMP production. The effect of
eta-blockers had a fast onset and led to a rapid reduction
f cAMP levels in cells stimulated with anti-1-ECII
ntibodies (Figs. 4A and 4C). However, even at saturat-
ng concentrations, all -receptor antagonists tested
locked the anti-1-ECII–induced effects only partially,
esulting in a 50% (alprenolol), 60% (bisoprolol), or up to b0% (carvedilol) reduction of the antibody-induced
pac-FRET signals (Figs. 4B and 4D). In contrast,
isoprolol was able to fully revert cAMP signals induced
y low-activating anti-1-ECI antibodies (Figs. 4E and
F). These data suggest that the clinically available
eta-blocking agents can only partially shield from the
armful high-activator antibody-induced cAMP produc-
ion in anti-1-ECII–positive patients, illustrating the
eed for novel, more specifically antibody-directed ther-
peutic strategies in heart failure.
Interestingly, when bisoprolol was added to cells pre-
reated with ECII peptides, the stimulatory effect of high-
ctivator anti-1-ECII antibodies on cAMP production was
ully blocked (Fig. 4D), indicating a synergistic effect
Figure 4 Effect of Beta-Blockers on
Anti-1-Abs–Induced Receptor Activation
Beta-blockers do not fully abolish the Epac-FRET signals in cells stimulated
with high-activator anti-1-Abs. Neither the selective 1-AR anatagonists biso-
prolol (Biso) (A) or metoprolol (Meto), nor nonselective drugs such as alpreno-
lol (C) (Alpren) or carvedilol (Carved) blocked more than 70% of the FRET
response induced by high-activator IgG under saturating conditions (3 mol/l).
Bisoprolol combined with ECII peptides, however, could fully block high-activa-
tor-induced FRET signals (Biso  ECII) (D). (B) Concentration-response curve
for the inhibitory effect of bisoprolol alone on high-activator-induced FRET sig-
nals. Data, means, and SEMs in (D) are calculated from at least 4 indepen-
dent experiments. (E) The stimulatory effect of low-activator IgG could be fully
abolished by bisoprolol. Representative experiments, n  6. Quantification is
shown in (F) together with the effect of a combination of bisoprolol with ECI
peptides (n  5). Abbreviations as in Figures 1 and 2.etween receptor peptides and -blockers. Such a combi-
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romising therapeutic approach.
iscussion
etection method and mechanisms of anti-1-Abs–
nduced receptor activation. Here we established a novel
RET-based method for the detection of functional anti-
1-Abs by measuring cAMP signals induced via 1-AR in
ntact cells. This method seems to be highly specific and
ensitive. The high sensitivity originates from 2 important
iological amplification mechanisms. First, signals from
eceptors to second messengers are often considerably am-
lified, making cAMP a sensitive indicator of 1-receptor
ctivation. Second, the high sensitivity of Epac-camps for
AMP makes it particularly capable of detecting changes at
ower cytosolic cAMP levels, while, like physiological
AMP effectors, it becomes saturated at higher levels of
AMP. Our novel single-step fluorescent method detected
unctionally active anti-1-Abs both in specifically immu-
ized rats and in patients with heart failure. It confirmed
arlier data on the presence of activating anti-1-Abs
argeting the second extracellular 1-receptor loop (anti-1-
CII) in about one-third of the patients with DCM, and in
smaller fraction of patients with ICM (10% to 20%).
oreover, the novel method unveiled a further class of
unctional anti-1-Abs directed against the first extracellu-
ar 1-receptor loop (anti-1-ECI) in about another third
36%) of DCM patients undetected by previous screening
ethods.
It is not yet clear how antibodies reacting with the
xtracellular loops of the 1-AR affect receptor activity. In
he 2-AR, amino acids in the transmembrane helices III,
, and VI have been assigned an anchoring function for
gonists (27). The second extracellular loop of the receptor
s predicted to form a -hairpin, which partly dips down
nto the ligand binding site, and thus might influence
eceptor–ligand interactions to some extent (28). The con-
ormation of this hairpin is thought to be stabilized by
ysteines situated in ECI and ECII. In the 2-AR, it has
een shown that reduction or mutation of one or several of
hese cysteines results indeed in a significant reduction of
gonist and antagonist affinities (29). Thus, in -AR correct
olding of the ECI and ECII loops may be essential for
orrect formation of the ligand binding pocket and might
xplain why antibodies directed against these loops can
nterfere with ligand binding, modulate receptor conforma-
ion, and thereby also modulate receptor activity (2,30).
iagnostic implications. Compared with the previously
eveloped ELISA/immunofluorescence/cAMP-RIA pro-
edure (6), the novel FRET-based method is simpler, less
ime consuming, and at least as precise (i.e., correctly
dentifying all patients previously considered anti-1-ECII–
ositive). The new method is based on detecting antibody-
nduced increases in cAMP. This second messenger most
ikely accounts for the harmful effects provoked by activating anti-1-Abs (1,31). In addition, by quantifying antibody-
nduced cAMP signals, the novel assay allows differentiation
etween functional anti-1-Abs classes (i.e., high and low
ctivators), which are presumably characterized by their
inding to distinct extracellular receptor domains. However,
tudies in larger patient populations will be required to
onfirm and elucidate further the relationship between
pitopes recognized by autoantibodies (1-ECI or 1-ECII,
espectively) and the extent of cAMP stimulation elicited by
hese antibodies. Furthermore, we cannot exclude in pa-
ients the occurrence of functionally relevant antibodies
eacting with epitopes other than 1-ECI or 1-ECII
2,25). Such antibodies might, in fact, be less (or not at all)
usceptible to the blocking peptides used in our study, and
hus might have been missed by our approach. On the other
and, the novel FRET method now offers the possibility of
esting a panel of different blocking peptides to identify
ther potential epitopes for functional receptor antibodies.
In summary, screening by Epac-FRET seems to repre-
ent a very sensitive single-step approach, allowing detec-
ion of different kinds of activating antibodies directed
gainst the human 1-AR.
herapeutic implications. In contrast to bisoprolol-
ensitive low-activator anti-1-Abs, neither 1-selective nor
onselective beta-receptor antagonists could fully block the
timulatory effects of high-activator anti-1-Abs: all beta-
lockers tested inhibited anti-1-ECII–mediated cAMP
roduction only partially (60% to 70%), with carvedilol
ppearing to be more effective than the other substances. A
ossible explanation for this finding might be different
allosteric) mechanisms by which antibodies or antagonists
ct on the receptor. By binding to the extracellular loops
istant from the agonist and antagonist ligand binding sites
n the transmembrane core of the receptor, anti-1-EC
ntibodies might in fact induce different types of conforma-
ional changes of the receptor molecule (1,30). In addition,
e cannot exclude in patients the occurrence of functional
ntibodies reacting with epitopes other than the extracellu-
ar loops (2,25), thereby leading to a confirmation of the
eceptor that prevents effective binding of beta-blocking
gents.
Although the inhibitory effects of -AR antagonists may
ontribute to their clinical effectiveness in anti-1-Abs–
ositive heart failure patients, the only partial inhibition of
nti-1-ECII antibodies should further stimulate research in
he field of specifically antibody-directed therapeutic strat-
gies. In addition to beta-blocking agents, such strategies
ight intend to eliminate stimulating anti-1-Abs by non-
elective or selective immunoadsorption (32,33), by
eceptor-homologous peptides (similar to those used in the
resent pilot study), or by direct targeting of the
utoantibody-producing B-cells themselves (34). In addi-
ion, our data provide a rationale for a combination therapy
ith beta-blockers and receptor peptides assuming a syner-
istic effect of the 2 approaches because bisoprolol fully
bolished the stimulatory effects of anti-1-ECII antibodies
o
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eptide (Fig. 4D).
linical implications. Evidence accumulated during the
ast 20 years suggests a pathophysiological relevance of
unctional anti-1-Abs in heart failure (2,25). Recent ex-
eriments in rats even indicate that activating anti-1-Abs
gainst the presumably antigenic 1-ECII loop (100%
equence-identity between human and rat) can actually
ause left ventricular dilatation and failure (1,24). However,
he clinical relevance of autoantibodies against myocyte
embrane antigens, including the 1-AR, has been difficult
o assess, because low titers of such antibodies also can be
etected in the healthy population as a part of the immu-
ologic repertoire (35).
Regarding activating anti-1-Abs, we show here that
heir prevalence is almost negligible in healthy subjects
2,6), even with a highly sensitive screening method. In
ontrast, we detected functional anti-1-Abs in about 20%
f patients with ICM (all of them high activators), and in
bout 70% of patients with DCM, half of them high
ctivators (apparently directed against 1-ECII), and about
nother half low activators (apparently directed against
1-ECI). It is conceivable that methodological differences in
creening for functional anti-1-Abs (which may comprise
utoantibodies directed against 1-ECII, 1-ECI, or against
oth epitopes) account for the wide range in anti-1-Abs
revalence rates reported earlier (2). The limited number of
atient sera analyzed in the present pilot study precludes a
alid estimation of the prognostic relevance of the newly
dentified anti-1-Abs classes. However, regarding the 12-
ear follow-up data of the here-analyzed 55 DCM patients,
e did not find any obvious differences in survival between
ntibody-negative and low-activator DCM patients (not
hown), whereas the presence of high-activator (anti-1-
CII) antibodies seemed to be associated with a worse
rognosis, which would corroborate our previous results
6,14). These preliminary findings on the possible clinical
elevance of different functional anti-1-Abs classes need to
e checked in large, well-characterized patient populations
study currently underway).
In conclusion, our novel fluorescence-based method for
he detection of functional anti-1-Abs is a fast, fully
unctional, and reliable live cell diagnostic assay with ex-
ected clinical impact, now facilitating robust large-scale
creening of heart failure patients.
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